Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Umberto Leone Roberti Maggiore, Stefano Salvatore, Franco Alessandri, Valentino Remorgida, Massimo Origoni, Massimo Candiani, Pier Luigi Venturini & Simone Ferrero. (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1387-1408.
Read now
Read now
Jacques Corcos, Javier C. Angulo, Alan D. Garely, Martin Carlsson, Jason Gong & Zhonghong Guan. (2011) Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion 27:5, pages 1059-1065.
Read now
Read now
Doreen E Chung & Alexis E Te. (2009) Tolterodine extended-release for overactive bladder. Expert Opinion on Pharmacotherapy 10:13, pages 2181-2194.
Read now
Read now
Articles from other publishers (22)
Wenjuan He, Guangliang Huang, Wenyan Cui, Yunfei Tian, Qian Sun, Xiaojuan Zhao, Yonghong Zhao, Dan Li & Xiuju Liu. (2023) Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. International braz j urol 49:5, pages 535-563.
Crossref
Crossref
Akvile Stoniute, Priya Madhuvrata, Madeleine Still, Evelyn Barron-Millar, Ghulam Nabi & Muhammad Imran Omar. (2023) Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2023:5.
Crossref
Crossref
Hadi Mostafaei, Hanieh Salehi-Pourmehr, Sandra Jilch, Greta Lisa Carlin, Keiichiro Mori, Fahad Quhal, Benjamin Pradere, Nico C. Grossmann, Ekaterina Laukhtina, Victor M. Schuettfort, Abdulmajeed Aydh, Reza Sari Motlagh, Frederik König, Claus G. Roehrborn, Satoshi Katayama, Pawel Rajwa, Sakineh Hajebrahimi & Shahrokh F. Shariat. (2022) Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology Focus 8:4, pages 1072-1089.
Crossref
Crossref
Hadi Mostafaei, Florian Janisch, Keiichiro Mori, Fahad Quhal, Benjamin Pradere, Sakineh Hajebrahimi, Claus G. Roehrborn & Shahrokh F. Shariat. (2022) Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus 8:1, pages 239-252.
Crossref
Crossref
Hadi Mostafaei, Keiichiro Mori, Fahad Quhal, Noriyoshi Miura, Reza Sari Motlagh, Benjamin Pradere, Ekaterina Laukhtina, Ivan Lysenko, Sajjad Ghaffari, Sakineh Hajebrahimi & Shahrokh F. Shariat. (2021) Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus 7:5, pages 1143-1156.
Crossref
Crossref
Andreas Wiedemann. 2021. Medikamente in der Urologie. Medikamente in der Urologie
145
169
.
. (2019) Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. Aktuelle Urologie 50:S 01, pages s11-s59.
Crossref
Crossref
Shingo Iino, Masayuki Kaneko & Mamoru Narukawa. (2018) Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis. International Urology and Nephrology 50:6, pages 1021-1030.
Crossref
Crossref
Shingo IINO, Masayuki KANEKO & Mamoru NARUKAWA. (2018) Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review. LUTS: Lower Urinary Tract Symptoms 10:1, pages 64-75.
Crossref
Crossref
Suvit Bunyavejchevin. (2017) Overactive Bladder Symptom Scores responsiveness before and after anticholinergic treatment in women with overactive bladder: The pilot study. Journal of Obstetrics and Gynaecology Research 43:7, pages 1189-1193.
Crossref
Crossref
Kyu Shik Kim, Eun Young Jang, Yong Tae Kim & Hong Sang Moon. (2016) Tamsulosin Treatment Affecting Patient-reported Outcomes in Benign Prostatic Hyperplasia-associated Depressive Symptoms. Urology 87, pages 172-177.
Crossref
Crossref
Miguel Orri, Craig H. Lipset, Bradly P. Jacobs, Anthony J. Costello & Steven R. Cummings. (2014) Web-based trial to evaluate the efficacy and safety of tolterodine ER 4mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials 38:2, pages 190-197.
Crossref
Crossref
Momokazu Gotoh, Toshimitsu Kobayashi & Keizo Sogabe. (2014) Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q). International Journal of Urology 21:5, pages 505-511.
Crossref
Crossref
Khaled Maman, Samuel Aballea, Jameel Nazir, Katia Desroziers, Mohamed-Elmoctar Neine, Emad Siddiqui, Isaac Odeyemi & Zalmai Hakimi. (2014) Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology 65:4, pages 755-765.
Crossref
Crossref
Nora Buser, Sandra Ivic, Thomas M. Kessler, Alfons G.H. Kessels & Lucas M. Bachmann. (2012) Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses. European Urology 62:6, pages 1040-1060.
Crossref
Crossref
Oussama El Yazami AdliJacques Corcos. (2012) Clinical Use of Tolterodine Extended Release in Overactive Bladder. Clinical Medicine Insights: Urology 6, pages CMU.S6425.
Crossref
Crossref
C. C. Sexton, S. M. Notte, C. Maroulis, R. R. Dmochowski, L. Cardozo, D. Subramanian & K. S. Coyne. (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. International Journal of Clinical Practice 65:5, pages 567-585.
Crossref
Crossref
Steven A. Kaplan, Tim Schneider, Jenelle E. Foote, Zhonghong Guan, Martin Carlsson & Jason Gong. (2011) Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International 107:9, pages 1432-1440.
Crossref
Crossref
Howard B. Goldman, Jon D. Morrow, Jason Gong, Li-Jung Tseng & Tim Schneider. (2011) Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU International 107:4, pages 598-602.
Crossref
Crossref
Josef Marencak, Nandini H. Cossons, Amanda Darekar & Ian W. Mills. (2011) Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Neurourology and Urodynamics 30:1, pages 75-82.
Crossref
Crossref
Sender Herschorn, Steven Swift, Zhonghong Guan, Martin Carlsson, Jon D. Morrow, Marina Brodsky & Jason Gong. (2009) Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial. BJU International 105:1, pages 58-66.
Crossref
Crossref
Peter K. Sand, Jon D. Morrow, Tamara Bavendam, Dana L. Creanga & Victor W. Nitti. (2009) Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal 20:7, pages 827-835.
Crossref
Crossref